Literature DB >> 212366

Antibody-dependent cellular cytotoxicity against Epstein-Barr virus-associated antigens in African patients with nasopharyngeal carcinoma.

G R Pearson, B Johansson, G Klein.   

Abstract

Antibody-dependent cellular cytotoxicity (ADCC) was performed on serum samples from African patients with nasopharyngeal carcinoma (NPC) to determine whether antibody titers determined by this assay might be of prognostic value in this disease. The serum donors were divided into two groups: (1) those individuals who died within 2 years following diagnosis of NPC; and (2) individuals who responded well to therapy and surivived for more than 2 years following diagnosis. The ADCC GMT for the survivor group was significantly higher than the GMT for non-survivors (%5,410 versus 615). Interestingly, there were a number of discordant sera in the non-survivor group that had very low ADCC titers (less than 240) at diagnosis in the presence of high VCA titers. When ADCC titers were compared with anti-EA or IgA antibody titers to VCA, a statistically significant inverse correlation was noted. These data suggest that ADCC titers might be of prognostic importance in African NPC.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 212366     DOI: 10.1002/ijc.2910220203

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

Review 1.  Relationship between antibody production to Epstein-Barr virus (EBV) early antigens and various EBV-related diseases.

Authors:  T Ooka; M de Turenne-Tessier; M C Stolzenberg
Journal:  Springer Semin Immunopathol       Date:  1991

2.  Epstein-Barr (EB) virus antibodies in rheumatoid arthritis.

Authors:  P B Ferrell; E M Tan
Journal:  Springer Semin Immunopathol       Date:  1981

3.  Antigenic specificity of antibody-dependent cell-mediated cytotoxicity directed against human immunodeficiency virus in antibody-positive sera.

Authors:  R A Koup; J L Sullivan; P H Levine; F Brewster; A Mahr; G Mazzara; S McKenzie; D Panicali
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

4.  Development of antibodies reactive in antibody-dependent cellular cytotoxicity in infectious mononucleosis.

Authors:  J F Hewetson; J F Böcker; P Sereni; C E Rapp; W Henle
Journal:  Infect Immun       Date:  1979-04       Impact factor: 3.441

5.  p105, an Epstein-Barr virus-induced, phosphonoacetic acid-insensitive glycoprotein target of the anti-Epstein-Barr virus immune response.

Authors:  D Casareale; W Jones; T Sairenji; R E Humphreys
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

Review 6.  Epstein-Barr virus (EBV)-specific cell-mediated and humoral immune responses in ataxia-telangectasia patients.

Authors:  G Masucci; I Berkel; M G Masucci; I Ernberg; R Szigeti; F Ersoy; O Sanal; O Yegin; G Henle; W Henle
Journal:  J Clin Immunol       Date:  1984-09       Impact factor: 8.317

7.  Epstein-Barr virus serology in nasopharyngeal carcinomas and other head and neck neoplasms in Italy.

Authors:  A Faggioni; C Corradini; G Barile; G Cardi; V Ciarniello; M Venenzoni; C Zompetta; M Maurizi; G Paludetti; V Manzari
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

8.  Natural and antibody-dependent cytotoxicity in different clinical stages of human immunodeficiency virus type 1 infection.

Authors:  K Ljunggren; A Karlson; E M Fenyö; M Jondal
Journal:  Clin Exp Immunol       Date:  1989-02       Impact factor: 4.330

9.  Failure of ADCC to predict HIV-associated disease progression or outcome in a haemophiliac cohort.

Authors:  A Dalgleish; A Sinclair; M Steel; D Beatson; C Ludlam; J Habeshaw
Journal:  Clin Exp Immunol       Date:  1990-07       Impact factor: 4.330

10.  Increased sensitivity of human lymphoid lines to natural killer cells after induction of the Epstein-Barr viral cycle by superinfection or sodium butyrate.

Authors:  B Blazar; M Patarroyo; E Klein; G Klein
Journal:  J Exp Med       Date:  1980-03-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.